https://icbii.com/2016/01/brain-imaging-tracer-for-parkinsons-disease/2016-05-17T00:19:20+00:00https://icbii.com/2016/05/icbi-to-receive-grant-from-michael-j-fox-foundations-2013-rapid-response-innovation-awards/2016-05-17T05:46:50+00:00https://icbii.com/2016/05/third-party-validation-of-bbb-permeability-and-target-specificity-of-sms-by-dr-eliezer-masliah-ucsd/2016-05-17T05:45:45+00:00https://icbii.com/2017/12/icbii-announces-the-filing-of-orphan-drug-designation-application-for-the-use-of-%ce%b1-synuclein-smart-molecule-in-the-treatment-of-multiple-system-atrophy/2017-12-06T23:34:00+00:00https://icbii.com/2018/12/icbii-announces-approval-of-two-us-patents-and-filing-of-two-divisional-patent-applications-in-europe/2019-02-28T20:50:03+00:00https://icbii.com/2019/03/2019-market-report-novel-technologies-for-delivery-of-proteins-antibodies-and-nucleic-acids-forecast-to-2030/2022-06-20T23:21:58+00:00https://icbii.com/2019/08/how-this-entrepreneur-is-working-to-cure-neural-diseases/2022-06-15T21:07:39+00:00https://icbii.com/2021/09/icbii-announces-approval-of-its-7th-patent-on-blood-brain-barrier-permeable-technology-moving-closer-to-clinical-trials-on-its-drugs-for-alzheimers-parkinsons-and-other-neuro-degenerative-disea/2022-06-21T18:19:05+00:00